Effects of CYP2C9 polymorphism on the pharmacokinetics of irbesartan in healthy Korean subjects

被引：0
|
作者：
Kim, Mi-Jung
Bae, Jung -Woo
Han, Ho-Kyun
Choi, Sun-Ok
Kim, Ok-Hee
Jang, Choon-Gon
Lee, Jin-Hee
Kim, Nam-Tae
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
Irbesartan; CYP2C9; polymorphism; pharmacokinetics;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [21] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Jung-Woo Bae
    Ji-Hong Kim
    Chang-Ik Choi
    Mi-Jeong Kim
    Hyung-Ji Kim
    Seong-Ae Byun
    Young-Soon Chang
    Choon-Gon Jang
    Young-Seo Park
    Seok-Yong Lee
    Archives of Pharmacal Research, 2009, 32 : 269 - 273
  • [22] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [23] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Pureum Kang
    Chang-Keun Cho
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Chang-Ik Choi
    Jung-Woo Bae
    Archives of Pharmacal Research, 2023, 46 : 438 - 447
  • [24] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Helene Sabia
    Gangadhar Sunkara
    Monica Ligueros-Saylan
    Yibin Wang
    Harold Smith
    James McLeod
    Pratapa Prasad
    European Journal of Clinical Pharmacology, 2004, 60 : 407 - 412
  • [25] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Sabia, H
    Sunkara, G
    Ligueros-Saylan, M
    Wang, YB
    Smith, H
    McLeod, J
    Prasad, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (06) : 407 - 412
  • [26] Effects of CYP2C9 genetic polymorphism on the pharmacokinetics of zafirlukast.
    Kim, Mi-Jung
    Jang, Choon-Gon
    Lee, Seok-Yong
    PHARMACOTHERAPY, 2012, 32 (10): : E234 - E234
  • [27] Effects of combined CYP2C9 and 2C19 polymorphism on the pharmacokinetics of glibenclamide in Chinese subjects.
    Yin, OQ
    Tomlinson, B
    Chow, MS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P23 - P23
  • [28] CYP2C9*3and*13 alleles significantly affected the pharmacokinetics of glipizide in healthy Korean subjects.
    Song, Y.
    Kim, N.
    Bae, J.
    Kim, M.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S68 - S69
  • [29] Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan
    Bae, Jung-Woo
    Han, Ho-Kyun
    Lee, Hwan-Joo
    Jung, Dong -Won
    Kim, Nam-Tae
    Lee, Jin-Hee
    Jang, Choon-Gon
    Choi, Sun-Ok
    Kim, Ok-Hee
    Lee, Seok-Yong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 230 - 231
  • [30] CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response
    Miners, J
    PHARMACOGENETICS, 2002, 12 (02): : 91 - 92
12345